ABCL Stock — AbCellera Biologics Inc. Common Shares: Cash, EV, Pipeline

Share price

$12.63

Market cap

$4,090.9M

Cash

$307.1M

Enterprise value

$3,783.8M

Balance sheet

Cash	$307.1M
Debt	$0.0M
Net cash	$307.1M
Enterprise value	$3,783.8M
Basic shares	306.5M shares
Fully diluted shares	417.0M shares
Fully diluted market cap	$5,266.5M
Cash per share	$1.00

Cash figures as of 2026-08-14. Database snapshot: 2026-09-21.

Price history

Loading ABCL daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
May 13 - Jun 24	ABCL575	Phase 1	Healthy Volunteers	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ABCL635

Phase 2 · Active Modality: antibody

Target NK3R

Indications

moderate-to-severe vasomotor symptoms associated with menopause (Stage not disclosed)

Status note Phase 1/2 program in moderate-to-severe vasomotor symptoms. Target/modality from 10-K fallback.

ABCL575

Phase 1 · Active Modality: fully human half-life-extended monoclonal antibody

Target OX40L

Indications

not disclosed (Stage not disclosed)

Catalysts

— None

Status note Target/modality from 10-K fallback.

ABCL688

Preclinical · Active Modality: antibody

Indications

undisclosed autoimmune indication (Stage not disclosed)

Catalysts

— None

Status note IND/CTA-enabling antibody candidate. Target undisclosed in current 10-Q; 10-K describes target as undisclosed GPCR or ion channel/multipass membrane protein.

ABCL386

Preclinical · Active Modality: antibody

Indications

undisclosed oncology indication (Stage not disclosed)

Catalysts

— None

Status note IND/CTA-enabling antibody candidate against undisclosed oncology target. Jazz and Vertex collaborations cover unnamed discovery programs (no candidate rows created).

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ABCL635
Lead indication	Vasomotor Symptoms Associated With Menopause
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07118891	Phase 2	Active, not recruiting	Sponsor	ABCL	—	Vasomotor Symptoms Associated With Menopause; Healthy Volunteers	—
NCT07108894	Phase 1	Active, not recruiting	Sponsor	ABCL	—	Healthy Volunteers	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for AbCellera Biologics Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	33,012,138	+2,736,200	1.30%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ABCL — AbCellera Biologics Inc. Common Shares

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders